IMC-C103C + atezolizumab

IMC-C103C + atezolizumab is an investigational combination therapy studied in patients with advanced, MAGE-A4-positive cancers who are HLA-A*02:01-positive. IMC-C103C is a bispecific ImmTAC (Immune mobilizing monoclonal TCRs Against Cancer) molecule comprising an affinity-matured soluble T cell receptor (TCR) specific for MAGE-A4 peptide presented by HLA-A*02:01 and fused to an anti-CD3 single-chain variable fragment (scFv). This design redirects polyclonal T cells to kill tumor cells expressing MAGE-A4. Atezolizumab is a monoclonal antibody targeting programmed death-ligand 1 (PD-L1), functioning as a checkpoint inhibitor that enhances anti-tumor T cell responses by blocking PD-L1-mediated immunosuppression. The combination is being studied to determine dose, safety, tolerability, pharmacokinetics, immune activity, and anti-tumor efficacy in solid tumors[1][2][5][9]. The combination is administered intravenously. The investigational program is co-developed by Immunocore and Genentech/Roche[2][5].